On July 31, INSILICO rose 5.09% in regular trading, trading at 44.52 HKD/share, with turnover of 43.21 million HKD. The stock rebounded after a cumulative decline of approximately 9% over the prior three trading sessions.

On the news front, the company's AI-driven pan-TEAD inhibitor ISM6331 was granted FDA Fast Track designation on July 29 for treating unresectable malignant pleural mesothelioma in adult patients who previously received anti-PD-1 antibody therapy and platinum-based chemotherapy. ISM6331 had already received FDA Orphan Drug designation in 2024. Additionally, the Phase 1 clinical data for ISM6331 has been accepted for oral presentation at the ESMO 2026 Annual Meeting scheduled for October 25 in Madrid. Meanwhile, the company's lead asset Rentosertib formally initiated its Phase 3 clinical trial on July 8 for idiopathic pulmonary fibrosis.

Within the Life Sciences Tools and Services sector, WUXI BIO up 1.53%, XTALPI up 2.33%, JOINN up 2.07%, GENSCRIPT BIO up 1.28%, WUXI APPTEC flat at 0%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)